New Drug 'ixekizumab' Offers Fast Improvement to People With Psoriasis

A trail of a new drug has reported quick and extensive improvement of the psoriasis skin condition, offering hope to thousands of people suffering from the disease.

The details published in The Lancet journal showed that 40% of people reported a complete clearance of psoriatic plaques after 12 weeks of treatment with the new drug and over 90% showed improvement.

New Test to Distinguish Psoriasis from Eczema Identified
Researchers have developed a new diagnostic procedure which in practice enables psoriasis and eczema to be reliably differentiated from one another on the basis of only two genes.

People with psoriasis develop thick, red skin with flaky, silver-white patches called scales which can be itchy for sufferers.

"The visible effects of psoriasis can have a major and life-ruining impact on people’s confidence and self-esteem," said lead researcher Chris Griffiths, professor of dermatology at University of Manchester in Britain.

The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept.

Onset and Progress of Psoriasis Influenced by Cells in the Skin
Researchers have revealed that different types of dendritic cells in human skin have varied functions in psoriasis.

"What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching - far more than in the other two groups," Griffiths added.

Around half of these patients in the trial showed improvement as early as week four of the trial and up to 71% had shown a high level of improvement, as measured using a scale called the Psoriasis Area and Severity Index, by week 12.

Health Experts Call Attention to Major Impact of Psoriasis on Quality of Life
Health experts gather for an event on psoriasis during the 67th World Health Assembly to highlight the impact psoriasis has on health-related quality of life.

Ixekizumab is a monoclonal antibody - a cloned antibody - which neutralizes the inflammatory effects of an interleukin (IL) a protein in the skin which carries signals to cells - known as (IL)-17A.

This protein is increasingly becoming recognized as one of the causes of the characteristic red, scaly plaques of psoriasis.

Risk of Psoriasis High Among Women With Hypertension
The risk of skin condition psoriasis is high among women who suffer from long-term high blood pressure and use beta- blocker medication to treat their condition.

Source-IANS